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Cell culture-based blood-brain barrier (BBB) models are useful tools for screening of
CNS drug candidates. Cell sources for BBB models include primary brain endothelial
cells or immortalized brain endothelial cell lines. Despite their well-known differences,
epithelial cell lines are also used as surrogate models for testing neuropharmaceuticals.
The aim of the present study was to compare the expression of selected BBB
related genes including tight junction proteins, solute carriers (SLC), ABC transporters,
metabolic enzymes and to describe the paracellular properties of nine different
culture models. To establish a primary BBB model rat brain capillary endothelial
cells were co-cultured with rat pericytes and astrocytes (EPA). As other BBB and
surrogate models four brain endothelial cells lines, rat GP8 and RBE4 cells, and
human hCMEC/D3 cells with or without lithium treatment (D3 and D3L), and four
epithelial cell lines, native human intestinal Caco-2 and high P-glycoprotein expressing
vinblastine-selected VB-Caco-2 cells, native MDCK and MDR1 transfected MDCK
canine kidney cells were used. To test transporter functionality, the permeability of
12 molecules, glucopyranose, valproate, baclofen, gabapentin, probenecid, salicylate,
rosuvastatin, pravastatin, atorvastatin, tacrine, donepezil, was also measured in the
EPA and epithelial models. Among the junctional protein genes, the expression level
of occludin was high in all models except the GP8 and RBE4 cells, and each model
expressed a unique claudin pattern. Major BBB efflux (P-glycoprotein or ABCB1) and
influx transporters (GLUT-1, LAT-1) were present in all models at mRNA levels. The
transcript of BCRP (ABCG2) was not expressed in MDCK, GP8 and RBE4 cells. The
absence of gene expression of important BBB efflux and influx transporters BCRP,
MRP6, -9, MCT6, -8, PHT2, OATPs in one or both types of epithelial models suggests
that Caco-2 or MDCK models are not suitable to test drug candidates which are
substrates of these transporters. Brain endothelial cell lines GP8, RBE4, D3 and
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D3L did not form a restrictive paracellular barrier necessary for screening small molecular
weight pharmacons. Therefore, among the tested culture models, the primary cell-based
EPA model is suitable for the functional analysis of the BBB.
Keywords: blood-brain barrier, brain endothelial cells, Caco-2, MDCK, RBE4, hCMEC/D3, gene expression, CNS
drug permeability
INTRODUCTION
The development and introduction of novel
neuropharmaceuticals lags behind other groups of medicines,
which is partially due to the poor central nervous system
(CNS) pharmacokinetics (Banks, 2016). One of the reasons
for the low number of CNS active drugs in clinical use is the
restricted penetration of most drugs across the blood-brain
barrier (BBB; Pardridge, 2015). The BBB is the major barrier
of the CNS and is composed of brain capillary endothelial
cells surrounded by pericytes embedded in the capillary
basal membrane, and astrocytic endfeet (Abbott, 2013). The
four main mechanisms at the level of the BBB to limit drug
transport are: (i) the restricted paracellular pathway regulated
by interendothelial tight junctions (TJ); (ii) the low level of
non-specific transendothelial vesicular traffic; (iii) active efflux
transporters which deliver metabolites from brain to blood and
prevent the entry of xenobiotics and drugs to the CNS; and
(iv) enzymes which metabolize drug molecules (Deli, 2011;
Banks, 2016).
There is a need for reliable methods in drug development to
screen drug candidates for BBB penetration, on the one hand,
and to determine if substances acting in the periphery do not
cross the BBB to avoid CNS side effects, on the other hand.
Models that predict brain penetration are also valuable tools to
study and develop new targeted nanoparticles that cross the BBB
(Veszelka et al., 2015). There are several types of models for BBB
permeability from in silico approaches to in vivo studies (Vastag
and Keseru, 2009; Veszelka et al., 2011; Avdeef et al., 2015).
An important novel field in BBB research is the use of
microfluidic devices and organ-on-chip models. These chip
devices with the possibility of fluid flow provide more realistic
and physiological culture conditions. In contrast to static culture
inserts, in dynamic in vitro BBB models the endothelial cells
are exposed to shear stress, induced by fluid flow, an important
regulator of barrier function (Cucullo et al., 2011). In dynamic
models higher transendothelial electrical resistance (TEER) and
lower permeability were reported in comparison to culture
insert based in vitro models (Cucullo et al., 2013; Booth and
Kim, 2014; Walter et al., 2016). Despite these advantages,
dynamic in vitro models have not been widely accepted for BBB
permeability screening in the pharmaceutical industry yet. None
of the existing dynamic in vitro BBB models utilizing channel
microfluidics (Griep et al., 2013; Prabhakarpandian et al., 2013;
Booth and Kim, 2014; Walter et al., 2016) or hollow fiber
cartridges (Cucullo et al., 2011, 2013) have been assessed for a
set of CNS penetrating and non-penetrating drugs with different
chemical properties to elucidate a translational standard for
permeability.
Cell culture BBB models are versatile tools in both basic
research and permeability testing of drugs (Deli et al., 2005;
Veszelka et al., 2011; Helms et al., 2016). A large number of
models were developed based on primary cultures of cerebral
endothelial cells or immortalized cell lines (Deli et al., 2005;
Veszelka et al., 2011; Helms et al., 2016). Among the brain
endothelial cell lines, the rat GP8 (Greenwood et al., 1996) and
RBE4 (Roux et al., 1994), and human hCMEC/D3 cells (Weksler
et al., 2005) are the best characterized and the most widely
used in BBB research. RBE4 rat brain microvessel endothelial
cells were employed for drug transport studies, while no drug
permeability data were published for GP8 cells (Veszelka et al.,
2011). The most studied BBB cell line, hCMEC/D3, is also used
in drug transport and uptake experiments (Weksler et al., 2013).
While the paracellular barrier is not strong in hCMEC/D3 cells,
treatment with LiCl, aWnt/β-catenin pathway activator increases
TJ protein expression and barrier function (Weksler et al.,
2013). The most complex in vitro BBB models are based on
primary cultures of brain capillary endothelial cells from bovine
(Dehouck et al., 1990), rat (Szabó et al., 1997), or porcine brain
(Hoheisel et al., 1998; Patabendige et al., 2013), which are used
in many models in co-culture with astrocytes and/or pericytes
(Nakagawa et al., 2009). A recent article gives an updated
overview on culture models of the BBB with guidelines for their
use in permeability studies (Helms et al., 2016). A big advantage
of primary BBB models is that they are complex and retain many
of the in vivo physiological characteristics of the BBB. However,
as compared to cell line models, they are more expensive, their
preparation requires more time and technical expertise (Avdeef
et al., 2015).
Since cost and test capacity are important factors in industrial
drug screening, models based on epithelial cell lines are still
used to predict permeability of CNS drug candidates (Vastag and
Keseru, 2009). The most widespread culture model of human
drug absorption is the Caco-2 human intestinal epithelial cell line
derived from a colon adenocarcinoma, which is used primarily
as a screening tool for small intestine absorption (Artursson
et al., 2001). For passive diffusion compounds, Caco-2 cells
give a good correlation even when compared with BBB models
(Garberg et al., 2005; Hellinger et al., 2012). Caco-2 cells
treated with vinblastine (VB-Caco-2), express a higher level of
P-glycoprotein and this model is a good predictor of ligands
for efflux transporters (Hellinger et al., 2010). The other cell
lines used in pharma industry for testing drug penetration are
the Madin-Darby canine kidney (MDCK) cell line and MDCK-
MDR1, a subclone transfected with the human MDR1 gene.
Using passive diffusion drugs MDCK cells gave a weaker
correlation as compared to BBB or Caco-2 models but in the
case of efflux transporter ligands the MDCK-MDR model gave
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accurate prediction (Garberg et al., 2005). Both Caco-2 and
MDCK cells form a tight paracellular barrier and overexpress
P-glycoprotein efflux pump, two factors participating in BBB
permeability regulation, therefore these epithelial models in
addition to prediction of intestinal absorption are also used as
surrogate models for the prediction of brain penetration (Vastag
and Keseru, 2009) despite cytoarchitectural differences and other
dissimilarities from BBB models (Hellinger et al., 2012).
The paracellular tightness of the various BBB models
measured by TEER and permeability (Pe/Papp) for marker
molecules is in general well characterized (Deli et al., 2005;
Helms et al., 2016). With the exception of P-glycoprotein, much
less is known about the efflux transporter expression pattern
and functionality in these models. Solute carriers (SLC) are
present at the BBB in high number, where they participate in
shuttling nutrients across brain endothelial cells (for review see
Campos-Bedolla et al., 2014). Despite their importance, SLC
expression and functionality in BBB models is understudied
(Helms et al., 2016). Even less is known about phase I and II drug
metabolizing enzymes in BBB culture models, with the exception
of hCMEC/D3 cells (Dauchy et al., 2009).
In our previous study, we compared a primary cell-based BBB
model in which rat brain endothelial cells were co-cultured with
pericytes and astrocytes (EPAmodel, Nakagawa et al., 2009) with
Caco-2, VB-Caco-2 and MDCK-MDR1 epithelial cell models
provided and highlighted differences in cellular morphology,
paracellular tightness and drug transport (Hellinger et al., 2012).
The aim of the present study was to extend these observations
with comparative data on the expression of selected BBB related
genes including TJ proteins, SLC and ABC transporters and
metabolic enzymes in nine different culture models. In addition
to EPA and epithelial models we also examined rat (GP8, RBE4)
and human brain endothelial cell lines (D3 andD3L). To test SLC
functionality the permeability of eleven drugs was also measured
in the EPA and epithelial models.
MATERIALS AND METHODS
Animals
For primary cultures of brain endothelial cells and pericytes
brains were obtained from 3-week old, for glial cell culture from
2-day old Wistar outbred rats. Organ removals were performed
following the regulations of the 1998. XXVIII. Hungarian law
and the EU Directive 2010/63/EU about animal protection
and welfare. Approval for animal studies was obtained from
the local animal health authority, the Governmental Office for
Csongrád County, Directorate of Food Chain Safety and Animal
Health (Permit numbers: XVI./03835/001/2006, XVI./834/2012).
Animals were fed on standard rodent chow and water ad libitum
and kept under a 12 h light/dark cycle in the conventional animal
house of the Biological Research Centre, Szeged.
Cell Cultures
Isolation of primary rat brain endothelial cells, glia and pericytes
and the construction of the in vitro BBB model were performed
according to the method described in our previous studies
(Nakagawa et al., 2009; Walter et al., 2015). After isolation, cells
were seeded on Petri dishes coated with 100 µg/ml collagen
type IV and 100 µg/ml fibronectin in sterile distilled water.
Brain endothelial cells were cultured in DMEM/ HAM’s F-12
(Gibco, Life Technologies, Carlsbad, CA, USA), 15% plasma-
derived bovine serum (PDS, First Link, Wolverhampton, UK),
100µg/ml heparin, 5µg/ml insulin, 5µg/ml transferrin, 5 ng/ml
sodium selenite, 1 ng/ml basic fibroblast growth factor (bFGF,
Roche, Basel, Switzerland) and 50 µg/ml gentamicin. During
the first 3 days of culture the medium of brain endothelial
cells contained 3 µg/ml puromycin to eliminate P-glycoprotein
negative, contaminating cell types (Perrière et al., 2005). Primary
rat brain pericytes were isolated using the same method as
for brain endothelial cells, except that pericytes were plated
onto uncoated Petri dishes (Orange Scientific, Braine-l’Alleud,
Belgium). Primary cultures of rat glial cells were prepared from
one-day-old Wistar rats (Perrière et al., 2005) and passaged to
10 cm Petri dishes (Corning, Costar, New York, NY, USA) coated
with 100 µg/ml collagen type IV in sterile distilled water and
cultured for 2 weeks before use for the triple co-culture model.
Pericytes and glial cells were cultured in DMEM/HAM’s F-12
supplemented with 10% fetal bovine serum (FBS, Pan-Biotech
GmbH) and 50 µg/ml gentamicin. For the triple co-culture
model, pericytes (P3) were passaged to the bottom side of
tissue culture inserts with 75 mm diameter (Transwell 3419,
polycarbonate membrane, 0.4 µm pore size, Corning Costar) at
a density of 1.5 × 104 cells/cm2. Endothelial cells were seeded to
the upper side of themembranes (7.5× 104 cells/cm2) and placed
to 10 cm Petri dish containing glial cells. Both compartments
received endothelial culture medium and the three types of
cells were cultured together for 4 or 5 days (Nakagawa et al.,
2009; Walter et al., 2015). In transport assays the triple culture
BBB model was prepared on 12 well plate Transwell inserts
(polyester membrane, 0.4 µm pore size, Corning Costar).
When brain endothelial cell layers became confluent 550 nM
hydrocortisone was added to tighten the junctions (Deli et al.,
2005).
GP8 rat brain endothelial cell line (provided by Dr. John
Greenwood, University College London, UK) was cultured in
DMEM/ HAM’s F-12, 15% PDS, 100 µg/ml heparin, 1 ng/ml
bFGF and 50 µg/ml gentamicin.
RBE4 rat brain endothelial cell line (provided by Dr. Pierre-
Olivier Couraud, Institut Cochin, Paris, France) was grown in
DMEM/ HAM’s F-12, supplemented with 10% FBS, 1 ng/ml
bFGF and 50 µg/ml gentamicin.
Cultures of human brain endothelial hCMEC/D3 cell line
(≤passage number 35) were grown in MCDB 131 medium
(Pan Biotech) supplemented with 5% FBS, GlutaMAX (100×,
LifeTechnologies, Carlsbad, CA, USA), lipid supplement (100×,
Life Technologies, Carlsbad, CA, USA), 10 µg/ml ascorbic acid,
550 nM hydrocortisone, 100 µg/ml heparin, 1 ng/ml basic
fibroblast growth factor (bFGF, Roche, USA), 2.5 µg/ml insulin,
2.5 µg/ml transferrin, 2.5 ng/ml sodium selenite and 50 µg/ml
gentamicin (Weksler et al., 2005). For differentiation of this cell
line (D3L group), the medium was supplemented with 10 mM
lithium chloride (LiCl) at the first change of medium (Paolinelli
et al., 2013). For the three brain endothelial cell lines, we used
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culture media with very similar or identical composition to those
that were originally described for their growth and maintenance.
Human Caco-2 intestinal epithelial cell line (ATCC cat.no.
HTB-37) was maintained in DMEM/HAM’s F-12 culture
medium supplemented with 10% FBS and 50 µg/ml gentamicin.
VB-Caco-2 cultures were created from Caco-2 cultures by
selecting cells with 10 nM vinblastine treatment for at least six
passages (Hellinger et al., 2010). Treatment leads to a more
homogeneous cell morphology and a higher expression level of
efflux pumps.
Parent and MDR1 transfected Madin-Darby canine kidney
epithelial cells (Evers et al., 2000) were obtained from the
Netherlands Cancer Institute (Amsterdam, Netherlands). The
tissue culture medium consisted of 4.5 g/l glucose containing
DMEM supplemented with 10% FBS, penicillin (50 units) and
streptomycin (0.05 mg/ml). For RNS isolation, all cell lines were
seeded in 10 cm Petri dishes and for transport assays cells were
passaged onto 12-well plate Transwell inserts coated with 0.05%
rat tail collagen in sterile distilled water.
Transendothelial Electrical Resistance
Measurement
Transendothelial electrical resistance (TEER), reflecting the
permeability of TJ for sodium ions, was measured by an
EVOM voltohmmeter (World Precision Instruments, Sarasota,
FL, USA) combined with STX-2 electrodes. Recorded resistance
was expressed to the surface area of the filters (Ω × cm2,
Transwell inserts, polystyrene membrane, 0.4 µm pore size,
Corning Costar, USA). TEER of cell-free inserts (110 Ω × cm2)
was subtracted from the measured data.
Permeability Measurement
For permeability tests the epithelial and endothelial cell types
were cultured on culture inserts (polycarbonate membrane,
0.4 µm pore size, 1.2 cm2 surface, Transwell, Corning Costar).
The inserts were transferred to 12-well plates containing
1.5 ml Ringer-Hepes buffer (EPA model) or HBSS-Hepes buffer
(epithelial models) in the lower (basal/abluminal) compartments.
In the upper (apical/luminal) compartments culture medium
was replaced by 0.5 ml buffer containing permeability marker
molecules albumin (1 mg/ml; Mw: 65 kDa) labeled with Evans
blue (167.5 µg/ml) and fluorescein (10 µg/ml; Mw: 376 Da).
After incubation with permeability markers for 30 min, samples
were collected from both compartments and concentrations
of the marker molecules were determined by a fluorescence
multi-well plate reader (Fluostar Optima; excitation wavelength:
485 nm, emission wavelength: 535 nm in the case of fluorescein
and excitation wavelength: 584 nm, emission wavelength: 680 nm
in the case of Evans-blue labeled albumin). The apparent
permeability coefficients (Papp) were calculated as we described
previously (Kürti et al., 2012). Briefly, cleared volume was
calculated from the concentration difference of the tracer in
the lower/basal compartment (∆[C]B) after 30 min (t) and
upper/apical compartments at 0 h ([C]A), the volume of the
lower/basal compartment (VB; 1.5 mL) and the surface area
available for permeability (A; 1.1 cm2) by the following equation:
Papp(cm/s) = [C]B × VBA× [C]A × t
For the permeability study on the EPA and epithelial
models, nine different SLC ligands (at 10 µM concentrations,
except glucopyranose (100 µM) and valproic acid (300 µM),
60–120 min) and two anticholinergic drugs, tacrine and
donepezil (0.5 µM, 30 min), approved for the treatment of
Alzheimer’s disease, were tested. The transport of tacrine and
donepezil was also measured in the presence of choline and
carnitine, two endogenous cationic metabolites to examine
whether they share influx transporters. The concentrations
of the test molecules in samples from the donor and
acceptor compartments were determined by high-pressure
liquid chromatography (HPLC) or liquid chromatography-mass
spectrometry (LC/MS). Papp was calculated for each drug as
described above. The efflux or permeability directional ratio
(PDR) was given as the ratio of Papp values in BA to AB direction
(Hellinger et al., 2012).
Immunohistochemistry
Brain endothelial and epithelial cells were cultured on rat tail
collagen coated glass cover slips. Endothelial cells were stained
for the integral membrane tight junction protein claudin-5 and
epithelial cells were stained for claudin-4. After the removal
of the culture medium cells were fixed with ethanol—acetic
acid (95:5 mixture) for 5 min at −20◦C, blocked with 3%
bovine serum albumin diluted in phosphate buffer (PBS) and
incubated overnight with primary antibodies: anti-claudin-5
(rabbit polyclonal antibody, 1:200, Sigma, AB_10753223) or anti-
claudin-4 (mouse monoclonal antibody, 1:200, Thermo Fisher
Scientific, AB_2533096). Incubation with secondary antibodies
Cy3-labeled anti-rabbit (Sigma) or Alexa488-labeled anti-mouse
immunglobulin (Invitrogen, Life Technologies, 1:500) and
Hoechst dye 33342 (Sigma) for nucleus staining lasted for 1 h.
Cells were washed three times with PBS between incubations.
After mounting the samples (Fluoromount-G; Southern Biotech,
Birmingham, AL, USA) staining was visualized by Olympus
Fluoview FV1000 confocal laser scanning microscope (Olympus
Life Science Europe GmbH, Hamburg, Germany).
RNA Isolation and Quality Control
The endothelial (primary brain endothelial cells, GP8, RBE4,
D3, D3L) and epithelial cells (Caco-2, VB-Caco-2, MDCK and
MDCK-MDR1) were cultured for 5 days in 10 cm dishes. After
reaching confluency cells were scraped, collected and cell pellets
were used for total RNA isolation using RNAqueous-4PCR
Kit (Ambion, Life Technologies, Austin, TX, USA) with
DNase1 (RNase-free) treatment according to the manufacturer’s
instructions. The concentrations and purity of the DNase-
treated RNA samples were assessed by a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Rockland, DE,
USA). The integrities of the isolated RNAs were characterized
using Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA,
USA). The RNA integrity numbers (RIN) were between 9.2 and
10 in the case of all studied RNA samples.
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Quantitative Real-Time Polymerase Chain
Reaction and Data Analysis
In all cases, cDNA synthesis was performed on 1 µg total
RNA samples by a High Capacity cDNA Reverse Transcription
Kit (Life Technologies) using random hexanucleotide primers
and MultiScribe Reverse Transcriptase in the presence of
RNase inhibitor according to the manufacturer’s protocols.
The expression of the selected BBB genes was analyzed by
quantitative PCR using TaqMan Low Density Array 384-well
microfluidic cards preloaded with TaqMan Gene Expression
Assays (Life Technologies). The list of the studied genes and
applied TaqMan Gene Expression Assays are shown in the
supplementary materials (Supplementary Table S1). Quantitative
real-time PCRs (qPCR) were performed by ABI TaqMan
Universal Master Mix (Life Technologies) using the ABI
Prism 7900 system (Applied Biosystems, Life Technologies).
qPCR data were analyzed using the ABI SDS 2.0 software
(Applied Biosystems, Life Technologies). In all samples the
expression of genes was normalized to 18S rRNA, which was
used as an endogenous control (∆Ct = Ctgene − Ct18S rRNA).
Expression values of studied genes were determined based on the
normalized expression of genes calculated with 2−∆Ct formula
which were correlated to the lowest normalized expression
measured by the applied qPCR method. For quantification
of the relative expression level of genes of interest, the
normalized expression data were analyzed using the comparative
∆∆Ct method (Livak and Schmittgen, 2001; Tóth et al.,
2014).
Statistical Analysis
Data are presented as means ± SEM or SD. Values were
compared using unpaired t-test, one-way or two-way analyses of
variances following Dunnett or Bonferroni multiple comparison
posttests (GraphPadPrism 5.0; GraphPad Software, USA).
Changes were considered statistically significant at P < 0.05. All
experiments were repeated at least two times and the number of
parallel samples was 4–8.
RESULTS
Comparison of the Triple Co-culture BBB
Model With Caco-2, VB-Caco-2, MDCK
and MDCK-MDR1 Epithelial Cell Lines:
Expression of Selected Tight Junction
Protein, Transporter and Metabolic
Enzyme Genes
Tight Junction Proteins
Primary rat brain endothelial cells grown in co-culture with glial
cells and pericytes (EPA) produced high levels of mRNA for key
tight junction proteins such as claudin-5 (CLDN5), occludin and
the endothelial cells specific adhesionmolecule ESAM (Figure 1).
Caco-2 epithelial cells also showed a high level of expression for
occludin, while in MDCK cells it was lower as compared to both
EPA and Caco-2 models (Supplementary Figure S1). The gene
of endothelial cell specific ESAM was expressed at a low level
in epithelial cells. High level of CLDN5 expression, comparable
to occludin and ESAM, was measured in brain endothelial
cells in the EPA model. In the BBB model, the cells expressed
low level of CLDN1, CLDN2, CLDN3, CLDN4 transcripts and
did not express CLDN7 mRNA, specific for epithelial cells.
The absence of CLDN16 transcript and relatively high level of
CLDN15 mRNA could be observed in the rat primary BBB
model (Figure 1). CLDN19 mRNA was detected in the rat BBB
model, but not in Caco-2 epithelial cells. The expression pattern
of claudins in MDCK cells was similar to that of the Caco-2
cells with some exceptions, CLDN2, CLDN5, CLDN16 and
CLDN19 gene expression levels were higher in the kidney
epithelial cells as compared to the intestinal epithelial cell lines
(Figure 1).
Solute Carrier or Other Transporters
In the BBB model, primary brain endothelial cells expressed high
levels of mRNAs for glucose transporter GLUT1 (Slc2a1) and
GLUT3 (Slc2a3; Figure 2) and the transcript level of GLUT5
(Slc2a5) was low. Caco-2 epithelial cells expressed high levels
of all three GLUT transporters from which GLUT5 showed
the highest and GLUT1 the lowest expression (Supplementary
Figure S2). MDCK cells also expressed high levels of the
GLUT1 gene, a low level of GLUT3, and did not express GLUT5.
Brain endothelial cells in co-culture expressed high amount
of mRNA coding monocarboxylic acid transporters MCT1
(Slc16a1), -2 (Slc16a2) and -6 (Slc16a6), which provide secondary
energy sources and thyroid hormones for the CNS, respectively
(Figure 2). Caco-2 epithelial cells expressed a high level of
MCT1 only and a lower level of MCT8 and MCT6 mRNAs.
MDCK cells did not produce the MCT1 transcript. In the
BBB model, high mRNA expression levels were measured for
all the amino acid transporters tested except for small neutral
amino acid transporter SNAT5 (Slc38a5), where a moderate
expression level was measured. Caco-2 and MDCK epithelial
cells also expressed all these transporter genes at a high and
moderate level. Among the peptide transport systems tested,
cells of the primary rat brain endothelial cell-based model did
not express PEPT1 (Slc15a1) but produced a significant amount
of PHT2 transcript (Slc15a3; Figure 2). In contrast, in the
Caco-2 cells the expression level of PEPT1 was relatively high,
but low in the case of PHT2. MDCK cell lines produced a
small amount of PEPT1 mRNA. Fatty acid transporter FATP1
(Slc27a1) was well expressed in the BBB and the epithelial models
(Figure 2). Among the sterol transporters, the ABCA2 gene
was expressed in all models, while the highest transcript level
of ABCA8 was found in MDCK cells, however, in the other
investigated models its transcript level was low. The gene of
MFSD2A, a transporter for ω-3 fatty acids was also transcribed
in all five models. Its expression level was higher in the Caco-2
and MDCK cells as compared to the EPA model (Figure 2).
Among the genes of Slc6 family rat brain endothelial cells
produced a high amount of mRNA of the gene of the carrier
for creatine (CRT, Slc6a8), and moderate transcript levels were
measured for glycine (GLYT1, Slc6a9) and taurine (TAUT,
Slc6a6) genes (Figure 2). A similar expression pattern was seen
for Caco-2 and MDCK epithelial cells. High levels of mRNAs
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FIGURE 1 | Relative transcript levels of selected genes encoding tight junction proteins measured by inventoried TaqMan Gene Expression Assays in a primary rat
brain endothelial cell-based blood-brain barrier (BBB) model (EPA) and in epithelial cell line models (Caco2, VB-Caco2, MDCK and MDCK-MDR1).
of the sodium-dependent vitamin transporter (SMVT, Slc5a6)
and vitamin C transporters ASCT2 (Slc1a5) and ASCT1 (Slc1a4;
Supplementary Table S2) genes were detected in rat brain
endothelial cells (Figure 2). Epithelial cells also expressed all
these carriers. Except for the absence of dopamine transporter
gene transcription (DAT, Slc6a3), low transcript levels of the
noradrenalin (NET, Slc6a2), serotonin (SERT, Slc6a4), and
GABA (GAT1, Slc6a1; GAT2, Slc6a13; GAT3, Slc6a11) genes
were seen in the BBBmodel (Supplementary Table S2). Epithelial
cells did not produce a detectable amount of mRNAs of the
genes of neurotransmitter carriers except for the high-level
expression of the SERT gene in Caco-2 cells (Supplementary
Table S2). The genes of organic anion-transporting polypeptides
(OATP1C1, Slco1c1; OATP1A2, Slco1a2) which mediate the
transport of thyroid and steroid hormones in addition to
organic anions, were expressed in primary brain endothelial
cells but not in epithelial models (Figure 2 and Supplementary
Table S2).
FIGURE 2 | Relative transcript levels of selected genes encoding solute carriers (SLC) and other nutrient transporters measured by inventoried TaqMan Gene
Expression Assays in a primary rat brain endothelial cell-based BBB model (EPA) and in epithelial cell line models (Caco-2, VB-Caco-2, MDCK and MDCK-MDR1).
NA: assay not available.
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FIGURE 3 | Relative transcript levels of selected genes encoding efflux transporters measured by inventoried TaqMan Gene Expression Assays in a primary rat brain
endothelial cell-based BBB model (EPA) and in epithelial cell line models (Caco-2, VB-Caco-2, MDCK and MDCK-MDR1).
Efflux Transporters
The BBB model EPA expressed a similarly high amount of
mRNA for the two primary efflux transporters at the BBB,
P-glycoprotein (Pgp, ABCB1) and breast cancer resistance
protein (BCRP, ABCG2; Figure 3). Vinblastine—selected VB-
Caco-2 cells showed significantly higher P-gp expression than
native Caco-2 cells, while MDCK-MDR1 cells transfected with
human ABCB1 gene also produced a higher level of canine
ABCB1 gene transcript (Figure 3, Supplementary Figure S3).
The expression of the BCRP gene could not be detected in the
kidney epithelial cells, but Caco-2 cells do express BCRP. Among
the tested multidrug resistance-associated proteins (MRP), the
mRNAs of the MRP-1, -3, -4 and -5 were the four most
dominant efflux transporter transcripts in brain endothelial cells,
the MRP-6 genes were expressed at a lower level, while the
MRP-2 gene was not expressed at all (Figure 3). Caco-2 cells
produced high amounts ofmRNAs of theMRP-2, -3 and -6, and a
lower level of MRP-1, -4 and -5 genes. MDCK cells had a similar
expression pattern to that of Caco-2 cells, except that they did
not transcribe theMRP-6 gene. Among the excitatory amino acid
transporters (EAAT, Slc1a family) which are participating in the
efflux transport of glutamate across the BBB and are responsible
for the low level of glutamate in the brain interstitial fluid, the
EAAT1 (Slc1a3) gene was highly expressed in brain endothelial
cells (Figure 3). The EAAT2 (Slc1a2) and EAAT3 (Slc1a1) genes
were expressed at moderate levels. In Caco-2 and MDCK cells
the expression level of EAAT3 gene was the highest. The gene
of EAAT1 was also highly expressed in Caco-2 cells, but not
expressed in MDCK cells. In contrast to the EPA model the
transcript level of the EAAT2 gene was very low in epithelial cell
lines.
Metabolic Enzymes
Among the tested genes of the phase-I drug metabolic enzymes,
brain endothelial cells of the EPA BBB model expressed
mRNA of CYP1A1, CYP2D6, CYP2R1, CYP2S1, CYP2U1 and
CYP27A1 cytochrome P450 enzymes (Figure 4, Supplementary
Figure S4), but not CYP1A2, CYP2E1 and CYP7A1. In Caco-2
cells the highest transcript level of the cytochrome P450 genes
was seen for CYP2S1 and CYP27A1 genes. Only two genes,
the CYP2C9 and CYP2D6 genes were transcriptionally active in
MDCK cells. The other genes either could not be tested inMDCK
cells due to the unavailability of appropriate gene probes or
they were not expressed. Among the genes of phase-II metabolic
enzymes selected, rat brain endothelial cells expressed high levels
of mRNA of the glutathione S-transferase pi (GSTP1 gene;
FIGURE 4 | Relative transcript levels of selected genes encoding metabolic enzymes measured by inventoried TaqMan Gene Expression Assays in a primary rat
brain endothelial cell-based BBB model (EPA) and in epithelial cell line models (Caco-2, VB-Caco-2, MDCK and MDCK-MDR1). NA: assay not available.
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FIGURE 5 | Relative transcript levels of selected genes encoding tight junction proteins measured by inventoried TaqMan Gene Expression Assays in a primary rat
brain endothelial cell-based BBB model (EPA) and in brain endothelial cell line models (GP8, RBE4, D3 and D3L).
Figure 4). Caco-2 cells expressed a high level of both GSTP1 and
GSTA1 genes of the glutathione S-transferase enzyme. The
expression level of the sulfotransferase 1A1 (SULT1A1) gene was
low in Caco-2 cells, moderate in EPA and high in the MDCK
cell lines. The expression level of the drug metabolizing enzyme
UDP-glucuronosyltransferase UGT1A1 gene was moderate in
the EPA model and high in Caco-2 cells (Figure 4). The relative
expression levels of all the measured genes in the BBB and the
epithelial models are shown in Supplementary Table S2.
Comparison of the Triple Co-culture BBB
Model With GP8, RBE4 and D3 Brain
Endothelial Cell Lines: Expression of
Selected Tight Junction Protein,
Transporter and Metabolic Enzyme Genes
Tight Junction Proteins
The expression level of occludin is high in the EPA and the
D3 models but low in the rat GP8 and RBE4 cell lines (Figure 5,
Supplementary Figure S5). The endothelial cell specific adhesion
molecule (ESAM) was expressed at high levels in all brain
endothelial cell models and was the highest in primary rat brain
endothelial cells. The level of CLDN5 mRNA was significantly
higher in the primary EPA model than in any of the cell
lines (Figure 5). The expression of the CLDN5 gene in the
RBE4 cell line was below the detection limit. Among the claudins,
the expression of the epithelial specific CLDN2 and -4 genes,
was lower in the endothelial than in the epithelial models,
while CLDN7 and CLDN16 was not expressed in the rat BBB
models, only in the human D3 cells (Figure 5). The CLDN1 and
CLDN11 genes were expressed in the EPA and D3 models, their
transcript levels were low in GP8 cells and absent in RBE4 cells.
With the exception of ESAM, occludin and CLDN15 all of the
tested TJ protein genes were not or expressed at low level in
the rat GP8 and RBE4 cell lines. The lithium treatment did not
change the transcript profile of the TJ protein genes in the D3L
model compared to the untreated D3 cells.
Solute Carriers and Other Transporters
The expression levels of glucose transporters GLUT1 and -3
genes were the highest in the EPA model. These two carriers
were also well transcribed in the other four cell lines, except for
GLUT3 in GP8 cells. In the D3 and GP8 models the primary
glucose transporter was GLUT1, while in RBE4 cells it was
GLUT3 (Figure 6, Supplementary Figure S6). The mRNA level
FIGURE 6 | Relative transcript levels of selected genes encoding SLC and other nutrient transporters measured by inventoried TaqMan Gene Expression Assays in a
primary rat brain endothelial cell-based BBB model (EPA) and in brain endothelial cell line models (GP8, RBE4, D3 and D3L).
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of the GLUT5 gene was low in all tested endothelial models, and
not expressed in RBE4 cells. The monocarboxylic acid carrier
MCT1 gene was also well expressed in all brain endothelial cells
except for RBE4. The MCT8 expression was the highest in the
EPA model. The MCT6 gene expression was at a moderate level
in all cell types.
From the seven amino acid transporters examined, high
expression level was measured for CAT1, LAT1 and SAT2 genes
in all models. In the human D3 cells, the expression of XCT,
SAT1 and SNAT5 genes was higher than in the rat BBB models.
The SN1 transcript level was high in the EPA model and
moderate in D3 cells. GP8 and RBE4 rat brain endothelial
cell lines expressed low level of SN1 and did not express
SNAT5. From the two tested peptide transporters PEPT1 was not
expressed in brain endothelial models (Figure 6). The PHT2 gene
expression level wasmoderate in the EPA andD3models and low
in GP8 and RBE4 cells.
The fatty acid transporter FATP1 gene was equally well
expressed in all BBB models. From the lipid transporters, the
ABCA2 gene was expressed in all models at a moderate level. The
highest mRNA level of ABCA8 was measured in D3 and D3L
cells. In the EPA model, the ABCA8 gene expression was low
and in GP8 and RBE4 cell lines it was not expressed. The highest
expression of the MFSD2A gene coding for the CNS transporter
for docosahexaenoic acid was measured in the D3 cells. The
transcription MFSD2A occurred at a moderate level in the EPA
model, but not in GP8 and RBE4 cells (Figure 6).
From the SLC6 family, moderate expression levels were
measured for the genes of creatine (CRT), glycine (GLYT1)
and taurine (TAUT) carriers in all brain endothelial cells
(Figure 6) except of the TAUT gene, which was expressed at
a low level in GP8 and RBE4 cells. The genes of the vitamin
transporters, SMVT and ASCT2 were well expressed in all
endothelial models, only the ASCT2 mRNA level was low in
GP8 cells (Figure 6). The gene of the organic anion-transporting
polypeptide OATP1C1 was expressed only in the primary EPA
model but not in the brain endothelial cell lines. Lithium
treatment in D3 cells elevated the expression level in half of the
tested carriers and transporter genes (GLUT3, -5, MCT8, SN1,
SNAT5, PEPT1, FATP1, ABCA2, GLYT1, TAUT, CRT, ASCT2;
Figure 6).
Efflux Transporters
The gene of one of the main efflux transporters of the BBB,
Pgp was well expressed in both the EPA (Abcb1a, Figure 7;
Abcb1b, Supplementary Table S3) and the D3models. The BCRP
gene expression was also high in the EPA but lower in the
D3models. Compared to the EPA and D3models, the expression
level of the Abcb1a gene was lower in the GP8 and RBE4 cells,
while the BCRP transcript level was below the detection limit in
these models (Figure 7, Supplementary Figure S7). The genes of
the ABC transporter subfamily C members MRP1, 3, 4, 5 were
well expressed in all models. The lowest expression for these
genes was seen in RBE4 cells. MRP2 was only expressed in
the D3 models. The MRP6 gene expression was the highest in
the primary EPAmodel, very low in the other endothelial models
and not detected in GP8 cells. The genes of the glutamate efflux
transporters EAAT1, -2, -3 were expressed at high and moderate
levels in the EPAmodel, lower levels inD3 cells and at a negligible
level in the rat brain endothelial cell lines (Figure 7). In D3 cells a
trend for elevation in gene expression was observed for MRP2, -6
and EAAT1, while an increase was seen in EAAT2 expression.
Metabolic Enzymes
We found two cytochrome P450 enzymes, CYP2U1 and
CYP27A1 from the tested 12 isoforms which were expressed in
all brain endothelial models (Figure 8, Supplementary Figure S8).
No gene expression was seen for Cyp1a2, Cyp2c11, Cyp2e1 and
Cyp7a1 genes in the EPA model, however these genes (CYP1A2,
CYP2C9, CYP2E1, CYP7A1) were expressed in D3 cells. In the
primary EPAmodel, the Cyp2d4, in D3 brain endothelial cells the
CYP2S1 and CYP2U1 transcript levels were the highest among
the genes of the selected phase I enzymes (Figure 8). GP8 cells
did not express Cyp genes except for the Cyp2d4, Cyp2u1 and
Cyp27a1 genes. In RBE4 cells only 3 Cyp enzyme genes, Cyp1a1,
Cyp2u1 and Cyp27a1, were well expressed, while the others were
expressed at very low or negligible levels.
The gene expression level of the GSTP1 phase II enzyme
was high in all models (Figure 8). The GSTA1, SULT1A1 and
UGT1A1 genes were expressed in the EPA and were absent or
very low in the other brain endothelial models (Figure 8).
Evaluation of the Barrier Integrity in Brain
Endothelial and Epithelial Models
Among the brain endothelial cell-basedmodels the TEERwas the
highest in the primary cell-based BBB model (475 ± 48 Ω cm2;
Table 1). Both native Caco-2 (854 ± 24 Ω cm2) and vinblastine
selected VB-Caco-2 (1186 ± 71 Ω cm2) models showed a tight
paracellular barrier. The MDCK, MDCK-MDR1, RBE4, D3 and
D3L cultures presented a TEER that was below 100 Ω cm2.
Treatment with lithium significantly elevated the TEER of
D3 cells (unpaired t-test, P < 0.0004). The lowest resistance was
measured in the GP8 cell line model. The EPA and the epithelial
models were the least permeable for both fluorescein, a low
molecular weight marker of paracellular integrity, and for Evans
blue-labeled albumin, the marker of transcellular permeability
(Table 1). All the four brain endothelial cell lines demonstrated
significant, one order of magnitude higher values of Papp for both
markers (Table 1).
The confluent, non-overlapping, uniform monolayer of
cells in all investigated models was well visible on both the
phase contrast images and the immunostainings for junctional
proteins (Figure 9). The most striking difference in the
pattern of endothelial cells compared to epithelial cells was
the cell shape. Endothelial cells were elongated, fusiform,
and formed a swirling pattern well observable on Figure 9.
Primary brain endothelial cells in the EPA model gave a
strong pericellular staining for claudin-5, the most abundant
claudin type at the BBB. Claudin-5 staining was concentrated
to the cell border at the interendothelial junctions. In the brain
endothelial cell lines, the claudin-5 staining was cytoplasmic
and not visible at the cell border (Figure 9, Supplementary
Figure S9). Epithelial cells presented characteristic ‘‘cobblestone’’
morphology. In accordance with the gene expression data
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FIGURE 7 | Relative transcript levels of selected genes encoding efflux transporters measured by inventoried TaqMan Gene Expression Assays in a primary rat brain
endothelial cell-based BBB model (EPA) and in brain endothelial cell line models (GP8, RBE4, D3 and D3L).
(Figure 1) epithelial cells stained intensely for claudin-4
(Figure 9), a TJ protein typical for epithelial cells.
SLC Related Drug Transport in the Culture
Models
The selected nine ligands for SLCs were tested on the BBB and
the four epithelial models. Drug penetration in the apical to
basal (A-B) direction (Papp) and the PDR ratio (PDR: Papp B-
A/Papp A-B) are shown in Table 2. The GLUT1 ligand 3-O-
methyl-D-glucopyranose was transported in all models. PDR
ratios indicating active influx was observed in the case of
EPA and Caco-2 models. Among the clinically used drugs in
the case of LAT1 substrates, the highest permeability values
were measured for valproic acid on all models (Figure 10).
Baclofen penetration was the highest in the EPA model, while
it was very low across the epithelial cell layers. In this group
of drugs, the lowest Papp was measured for gabapentin on all
models. None of the LAT1 ligand drugs were identified as
efflux pump ligands based on the PDR (Table 2). To further
prove the functionality of LAT1, L-DOPA (3, 4-dihydroxy-L-
phenylalanine) transport was measured in the EPA model in two
FIGURE 8 | Relative transcript levels of selected genes encoding metabolic enzymes measured by inventoried TaqMan Gene Expression Assays in a primary rat
brain endothelial cell-based BBB model (EPA) and in brain endothelial cell line models (GP8, RBE4, D3 and D3L).
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TABLE 1 | Paracellular tightness of different brain endothelial and epithelial cell culture models measured by transendothelial/epithelial electrical resistance (TEER) and
permeability for markers fluorescein and albumin.
Models TEER (Ω × cm2) Fluorescein Papp (10−6 cm/s) Albumin Papp (10−6 cm/s)
EPA 475 ± 48 2.1 ± 0.25 0.2 ± 0.03
CaCo2 854 ± 24 1.5 ± 0.28 0.8 ± 0.09
VB-CaCo2 1186 ± 71 0.3 ± 0.06 0.2 ± 0.08
MDCK 72 ± 9 2.8 ± 0.23 0.6 ± 0.05
MDCK-MDR1 81 ± 7 2.7 ± 0.31 -
GP8 28 ± 13 39.8 ± 3.51 16.5 ± 7.51
RBE4 64 ± 5 27.4 ± 1.63 3.9 ± 0.23
D3 45 ± 2 22.2 ± 3.71 2.1 ± 0.31
D3L 86 ± 6 19.3 ± 1.22 1.7 ±0.12
Papp: apparent permeability coefficients. Values are presented as mean ± SD.
directions. We observed a high Papp in A-B direction (73 ± 4
10–6 cm/s) and a low PDR (0.4). The second highest Papp value
was measured for the organic anion probenecid, especially in
the Caco-2 models (Table 2). The other organic anion, salicylic
acid had a low permeability in the BBB model as compared
with the epithelial models (Figure 10). Among the tested three
statins, rosuvastatin and pravastatin had significantly higher Papp
in the BBB model than in the Caco-2 or MDCK cells. In the
statin group the lowest Papp value in A–B direction and the
highest PDR (1.4) was measured for atorvastatin in the EPA
model, indicating that atorvastatin may be the subject of active
efflux transport. Parallel to the low penetration, the PDR for
FIGURE 9 | Different types of brain endothelial and epithelial cell cultures examined by phase contrast microscopy and stained for tight junction proteins CLDN5 (red)
and CLDN4 (green), and cell nucleus (blue). The CLDN5 immunostaining was well visible on the cell border of RBEC cells, while it was very weak or undetectable in
the brain endothelial cell lines. MDCK and Caco-2 epithelial cells showed an intense staining for CLDN4. Bars: 50 and 100 µm (phase contrast pictures); 20 and
50 µm (immunostaining pictures).
Frontiers in Molecular Neuroscience | www.frontiersin.org 11 May 2018 | Volume 11 | Article 166











































































































































































































































































































































































































































































































































































































































































































the statins was higher in the epithelial than in the BBB model
(Table 2).
We tested the penetration of two additional SLC ligands,
the organic cation tacrine and donepezil on the EPA and
VB-Caco-2 models (Figure 11A). The Papp of these two
anticholinergic CNS drugs were high among the tested SLC
related drugs in the EPA model (donepezil: 63 ± 13 10–6
cm/s; tacrine: 102 ± 27 10–6 cm/s). In primary brain
endothelial cells significantly higher Papp values were measured
for both drugs compared to those of the epithelial cells. The
permeability of donepezil was higher in the A-B direction
(blood-to-brain) in the BBB model indicating preferential influx
transport. In the epithelial model the donepezil permeability
was higher in the opposite, B-A (brain-to-blood) direction as
reflected in their PDR values (0.85 in EPA vs. 1.78 in VB-
Caco-2). In the BBB model the penetration of both drugs
could be inhibited significantly with the endogenous cationic
metabolites/nutrients choline and carnitine (Figure 11B),
indicating that the drugs and the endogenous ligands may share
common transporter(s).
DISCUSSION
A large number of BBB culture models are used in basic
as well as applied research and detailed characterization and
comparative datasets are needed to select the appropriate model
for a particular research aim. However, such studies are scarce.
The present work on nine different primary cell and cell
line-based models is unique, no such comparative study with
gene expression data, paracellular tightness and drug transport
has been published previously.
Comparison of EPA BBB Model to
Epithelial and Brain Endothelial Cell Lines:
TJ Pattern and Paracellular Barrier
Tightness
Our results confirm that the mRNA pattern of TJ proteins
in the primary culture-based EPA BBB model differs from
the pattern seen in epithelial cells (Figure 12). In the Caco-2
and MDCK cells the highest expression was measured for
CLDN1, CLDN3, CLDN4 and CLDN7 genes, which is a typical
pattern for intestinal epithelium in vivo (Chiba et al., 2008). In
contrast to Caco-2 epithelial cells and in agreement with brain
capillary data CLDN19, which has a tightening potential could
be detected in the rat BBB model (Ohtsuki et al., 2008). Despite
the different TJ transcript patterns, the TEER of epithelial cells,
except for MDCK cells, was well above the critical threshold
value of 150–200 Ω cm2, signifying a paracellular integrity
necessary for permeability assays (Gaillard and de Boer, 2000;
Deli et al., 2005). The reason for the low TEER value of
the kidney epithelial cells is the high expression of the genes
encoding the pore forming CLDN2, CLDN7 and CLDN16 which
facilitate cation permeability, thereby decrease TEER (Krause
et al., 2008). In spite of the low TEER values, MDCK cells
form a tight paracellular barrier for small marker molecules
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FIGURE 10 | Permeability coefficients (Papp) for selected drugs on primary rat brain endothelial cell-based BBB model (EPA) and in epithelial cell line models (Caco-2,
VB-Caco-2, MDCK and MDCK-MDR1) measured in the apical to basal (blood-to-brain) direction. Statistics: mean ± SD, n = 4, ANOVA and Dunnett test; ∗P < 0.05,
∗∗P < 0.01; ∗∗∗P < 0.001 compared to control.
of passive permeability (Veszelka et al., 2011; Hellinger et al.,
2012).
In agreement with literature data on gene expression of
rodent brain microvessels (Enerson and Drewes, 2005; Ohtsuki
et al., 2008) and according to our expectations the endothelial
specific ESAM and CLDN5 were measured in the EPA at
the highest expression level. ESAM was described as a cell
surface protein present at interendothelial cell contacts (Nasdala
et al., 2002). It is expressed in all vascular endothelium.
ESAM immunostaining was localized to the cell border in
bEnd.3 mouse brain endothelial cell line, and co-localized
with TJ proteins claudin-5 and occludin in mouse brain
capillaries by electron microscopy (Nasdala et al., 2002). While
claudin-5 is known to tighten BBB, no functional data are
known on how ESAM contributes to brain endothelial barrier
tightness.
The only transmembrane TJ protein that was unequivocally
proven to contribute to the restriction of hydrophilic small
molecule permeability at the BBB in vivo is claudin-5
(Nitta et al., 2003), this was the reason why we selected
CLDN5 protein for immunostaining. CLDN5 immunostaining
was well visible on the cell border of brain endothelial
cells in co-culture indicating junctional tightness verified by
TEER and permeability measurements. The low expression
level of the CLDN5 and occludin genes measured in all the
immortalized brain endothelial cell lines is responsible for
the weak paracellular barrier properties, the low TEER and
the high permeability values. In accordance with the gene
expression data, the CLDN5 immunostaining was very weak
or undetectable in these cells. Since these cell lines do not
form a restrictive paracellular barrier, they are not suitable
for screening small molecular drug candidates (Veszelka et al.,
2011).
In the case of brain endothelial cell lines, culture media
that were originally described for them were used. The culture
medium of the D3 cell line contained more supplements than
the medium of the primary brain endothelial cells. Despite this
complex medium D3 cells still did not form a tight barrier,
indicating that the cells’ intrinsic properties are responsible
for the weak junctions. To improve barrier properties, brain
endothelial cell lines have already been examined in co-culture
conditions. Co-culture data on the rat cell lines, RBE4 and
GP8, were summarized in our previous review (Deli et al.,
2005). In RBE4 cells the permeability of the sucrose marker
molecule was in all conditions higher than the accepted level
for small molecule testing (Deli et al., 2005). Co-culture of
GP8 rat brain endothelial cells with C6 glioma still resulted
in very low TEER and high fluorescein permeability values
(Deli et al., 2005). These data indicate, that the weak barrier
properties of these two rat cell lines were not significantly
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FIGURE 11 | Permeability coefficients (Papp) for donepezil and tacrine on
primary rat brain endothelial cell-based BBB model (EPA) and epithelial cell line
VB-Caco-2 (A). Transport of donepezil and tacrine in the presence of choline
(50 µM) and L-carnitine (50 µM) on the EPA model (B). Statistics: mean ± SD,
n = 4, two-way ANOVA and Bonferroni test; ∗∗P < 0.01; ∗∗∗P < 0.001
compared to control; #P < 0.05 compared to EPA.
improved by astrocytic influence. The basic permeability of
D3 monolayers is about 10 times higher for small molecule
tracers than in primary BBB models (Helms et al., 2016),
similarly to our findings. Co-culture of D3 cells with both human
astrocytes and pericytes did not elevate TEER as compared
to mono-cultures (Hatherell et al., 2011; Helms et al., 2016).
Taken together, these literature data indicate, that cell culture
supplements and co-culture conditions do not improve the
barrier tightness of the examined brain endothelial cell lines to
such an extent that they would be suitable for drug penetration
screening.
Comparison of EPA BBB Model to
Epithelial and Brain Endothelial Cell Lines:
Efflux Transporters
Pgp and BCRP were identified as the two primary efflux
transporters at the BBB in both human (Shawahna et al., 2011;
Uchida et al., 2011) and rat brain microvessels (Enerson and
Drewes, 2005; Hoshi et al., 2013). The rat EPA BBB model
expressed a similarly high amount of mRNA for Pgp and BCRP.
In native Caco-2 cells the expression of Pgp and BCRP genes
was lower than in the EPA model (Figure 12). Vinblastine
treatment significantly elevated the Pgp gene expression in VB-
Caco-2 cells in agreement with the literature data (Hellinger et al.,
2010). MDCK-MDR1 cells also expressed a higher level of the
ABCB1 gene that can contribute to the high efflux potential of
this cell line in agreement with our previous results (Hellinger
et al., 2012). In the MDCK and MDCK-MDR1 cell lines the
mRNA levels of ABCB1 determined by RT-qPCR and protein
levels of Pgp determined by Western blot correlated very well
(Gartzke and Fricker, 2014), suggesting that for this important
BBB efflux pump mRNA levels may reflect well protein levels.
We have verified in our previous work that Pgp protein is
present in the rat EPA BBB model, and in the VB-Caco-2 and
MDCK-MDR1 cells (Hellinger et al., 2012). In addition to Pgp,
MRP1 was demonstrated at protein level by both Western
blot and immunohistochemistry in our EPA model (Nakagawa
et al., 2009). The canine kidney cells did not express BCRP,
as it was demonstrated in an independent study (Quan et al.,
2012), which should be taken into account for drug efflux
studies. In the epithelial cell lines, the most dominant efflux
transporters were MRP2 and MRP3, while in the EPA model
MRP1 andMRP5. The data on epithelial cells are in concordance
with the findings of Hayeshi et al. (2008) and Quan et al.
(2012).
In RBE4 cells the Pgp mRNA expression was the lowest
among brain endothelial cell lines, the BCRP gene expression
was below the detection limit, and the transcript level of other
ABC transporters was also low. In GP8 cells also lower Pgp
mRNA level was measured, while BCRP and MRP6 genes
were not expressed. Based on these data the usage of rat
RBE4 or GP8 cell lines for (efflux) drug screening is not
suggested. We measured a high gene expression for Pgp in the
human D3 cell line and they also expressed BCRP. In D3 cell
plasma membrane fractions high protein expression for Pgp,
MRP1 and MRP4 were measured by LC-MS/MS-based protein
quantification analysis (Ohtsuki et al., 2013), supporting our
present mRNA findings.
EAAT transporters participate in the efflux transport of
glutamate across the BBB and are responsible for the low
level of glutamate in the brain interstitial fluid (Helms et al.,
2017). L-glutamate is taken up via EAAT1 at the abluminal
membrane of brain endothelial cells and exits at the luminal
membrane via a low affinity glutamate/aspartate transporter.
Among EAAT transporter genes, the EAAT1 gene was expressed
at the highest level in brain endothelial cells while in Caco-2
and MDCK cells the expression level of EAAT3 was the
highest. The mRNA level of the EAAT2 was very low in
Caco-2 cells and it was not expressed in MDCK cells. In
contrast to the EPA BBB model, the expression of EAAT
genes was negligible in brain endothelial cell lines except
for D3 cells in which the EAAT3 gene was expressed at a
low level. Our results support the findings of Helms et al.
(2012). They demonstrated the presence of EAAT1, -2 and -3
mRNA in brain endothelial cells by conventional RT-PCR
and the localization of EAAT1 and -3 in endothelial cells by
immunostaining.
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FIGURE 12 | Comparison of the expression of selected BBB genes between the primary rat brain endothelial cell-based EPA model and the human brain endothelial
cell line D3 (A), and the human intestinal cell line Caco-2 (B) measured by inventoried TaqMan Gene Expression Assays. The figure shows the ratio between the
gene expression level of tight junction proteins (TJ, red square), influx transporters (IT, blue dot), efflux transporters (ET, green triangle) and selected metabolic
enzymes (ME, yellow diamond) in EPA and D3 or Caco-2 cells. The graph also displays the expression values in the EPA sample on the y-axis to demonstrate the
level of expression of studied genes.
Comparison of the EPA BBB Model to
Epithelial and Brain Endothelial Cell Lines:
Metabolic Enzymes
Endothelial cells of brain capillaries express enzymes that are
capable of modifying drugs and xenobiotics that could bypass
the BBB and thereby protect the CNS from the potential harmful
effects of these molecules (Deli, 2011). Specific phase I and
phase II enzymes participate in the formation of this metabolic
barrier, with a supposed role in local drug metabolism and
transport. Our data confirm that cultured brain endothelial
cells express genes for phase-I and phase-II drug-metabolizing
enzymes in levels comparable to epithelial cells (Figure 12).
Among the cytochrome P450 enzymes, the CYP2D6 and the
CYP2U1 mRNA levels were the highest in the EPA BBB
model. CYP2D6 is involved in the hepatic metabolism of many
clinically used drugs, while CYP2U1 is an extrahepatic isoform
expressed in the thymus and brain, whichmetabolize arachidonic
acid and other long chain fatty acids (Dauchy et al., 2009).
In Caco-2 cells, the gene of extrahepatic CYP2S1 enzyme,
which metabolizes naphthalene, was expressed at the highest
level. Only two enzyme genes, CYP1A2 and CYP2E1 could be
tested in MDCK canine cells, which were not expressed. Gene
probes for other CYP enzymes in this species were unavailable.
In D3 cells the CYP2S1 and the CYP2U1 genes were most
dominantly expressed, in concordance with the data of Dauchy
et al. (2009). In GP8 and RBE4 cell lines all the genes of
the tested phase-I enzymes were expressed at very low or
negligible levels except for the CYP1A1 gene in RBE4 cells,
which encodes an enzyme metabolizing arachidonic acid and
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other polyunsaturated fatty acids into signaling molecules. We
found in a previous work that the arachidonic acid metabolism
and the vasoactive properties of GP8 and RBE4 cell lines are
altered compared to primary brain endothelial cells (Kis et al.,
1999).
From the tested phase-II metabolic enzymes involved in the
cellular detoxification processes, the glutathione S-transferase
pi (GSTP1) gene was expressed at the highest level in the
EPA model. GSTP1 is expressed in brain capillaries, where
it colocalizes to a large extent with MRP2 at the luminal
plasma membrane of brain endothelial cells (Bauer et al., 2008).
Colocalization and coordinated upregulation of MRP2 and
GSTP1 by pregnane X receptor activation suggest functional
coupling of this metabolizing enzyme and efflux transporter
(Bauer et al., 2008). In Caco-2 cells, the genes of tested phase-II
metabolic enzymes were transcribed at high levels, except
SULT1A1. GSTP1 gene expression was high in brain endothelial
cell lines. GSTA1, SULT1A1 and UGT1A1 genes were expressed
in the EPA, but were absent or detected at very low level in
brain endothelial cell lines. Summarizing these data, phase-I and
phase-II metabolic enzymes are expressed in brain endothelial
cells of the EPAmodel, suggesting a role in the regulation of local
drug transport.
Comparison of the EPA BBB Model to
Epithelial and Brain Endothelial Cell Lines:
Influx Transporters and Drug Permeability
In the present study, we compared the expression levels of
25 influx and 11 efflux transporter genes in nine different culture
models. To check the functionality of these transporters we
tested nine different drugs on EPA, Caco-2 and MDCK cells,
which showed the best paracellular tightness properties among
the models. We excluded the brain endothelial cell lines, because
they did not form a restrictive paracellular barrier to screening
the permeability of small molecules.
The dominant SLC transporter for hexoses at the mammalian
BBB is the GLUT1, which provides D-glucose, the primary
source of energy for brain functions (Shawahna et al.,
2011). The EPA model, expressed the highest level of the
GLUT1 gene of all the models. We have previously verified
the presence of GLUT1 protein by both Western blot and
immunohistochemistry in the EPA model (Nakagawa et al.,
2009). GLUT3 mRNA was also present in this BBB model,
but at a lower level, in concordance with rat and human
brain microvessel gene and protein data (Enerson and Drewes,
2005; Shawahna et al., 2011; Uchida et al., 2011; Hoshi et al.,
2013). In contrast to BBB data, we found that in Caco-2 cells
GLUT3 and GLUT5 are the dominant hexose transporters, not
GLUT1. Similar mRNA data were obtained on Caco-2 cells
by other groups (Hayeshi et al., 2008). SLC transporter genes,
that were expressed at a high mRNA level in our study, like
GLUT-1, MCT-1, LAT-1 and PEPT1 were all demonstrated in
Caco-2 cells by proteomic analysis, too (Ölander et al., 2016).
Moreover, a correlation was found between normalized mRNA
rank and normalized protein abundance rank in Caco-2 cells
for selected SLC genes (Ölander et al., 2016). The renal MDCK
cell line expressed GLUT1 at high level, as it was already
published (Quan et al., 2012), but not the other two GLUT
transporters.
Similarly to the primary BBB model, the dominant glucose
transporter in D3 cells was also GLUT1, in agreement with
literature data (Carl et al., 2010; Urich et al., 2012; Ohtsuki
et al., 2013). In GP8 cells the main glucose transporter was also
GLUT1, while in RBE4 cells it was GLUT3. In RBE4, as well as in
primary rat brain endothelial cells, both the 55 kDa GLUT1 and a
45–50 kDa band corresponding to brain GLUT3were detected by
Western blot analysis (Régina et al., 2001), in concordance with
our mRNA findings. The expression level of the GLUT5 gene
was low or not detectable in the endothelial cell lines. We
tested GLUT1 functionality on the EPA model, and using
glucopyranose as a transporter ligand (Bidder, 1968) we found
a higher Papp value as compared to the epithelial cell lines and
a very low PDR value, suggesting influx transport. These data
are the first functional results on GLUT1 in a rat BBB culture
model. The functionality of GLUT1 was only proved on bovine
and human stem cell-based BBB culture models so far (Helms
et al., 2016).
The MCT transporter family provides the CNS with the
secondary energy source ketone bodies, like lactate, and also with
thyroid hormones. Lactate is used by the human brain during
development and the postnatal period, and in adult life during
starvation, diabetes and ischemic insults to maintain energy
homeostasis in the CNS (Campos-Bedolla et al., 2014). Lactate is
bidirectionally transported by MCTs, among which the principal
transporter at the BBB is MCT1 both in rodents and humans
(Enerson and Drewes, 2005; Dahlin et al., 2009; Shawahna et al.,
2011). The EPA model expressed high levels of all three tested
MCT genes. Caco-2 cells expressed MCT1 at a lower level, and
much less MCT8 and -6. MDCK cells did not express MCT1. In
contrast, all brain endothelial cells except RBE4 expressed this
transporter well. Besides monocarboxylates, MCTs participate
also in the transport of drugs like salicylic acid or probenecid
at the BBB (Enerson and Drewes, 2003; Bhattacharya and Boje,
2006). The functional presence of the MCT transporters at the
EPA model was proved by the moderate permeability rate of
probenecid, an organic anion, and a ligand forMCTs and organic
anion transporter systems (OAT, SLC22; Deguchi et al., 2000).
The low permeability of salicylic acid, a substrate for MCT1,
OATP2 and MRP4 at the EPA model might be explained by the
potential counteracting vectorial transport of SLC transporters
and MRP efflux pumps. Significantly higher permeability was
measured for probenecid on the Caco-2 cell lines, and for salicylic
acid on the epithelial cells than on the BBB model, which might
be explained by the different expression pattern for SLC and ABC
transporters in the BBB model vs. epithelial cell lines.
All models expressed high levels of SLC transporters for
amino acids, with significantly higher levels of large amino acid
transporters CAT1, LAT1 and small amino acid transporters
SAT2 and SN1 in the EPA model compared to epithelial
models. The expression of LAT1 gene is the highest SLC
in human brain microvessels (Shawahna et al., 2011), and is
approximately 100-fold greater than in other tissues. LAT1, the
most abundant amino acid carrier, is selectively expressed on
both plasma membranes of brain capillaries. LAT1 supplies
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leucine, tryptophan, tyrosine and phenylalanine to the brain
and participates in the transport of drugs like L-DOPA,
baclofen, valproic acid and gabapentin across the BBB (Ohtsuki
and Terasaki, 2007). L-DOPA, a well-known example of
LAT1 substrates, gave the highest Papp value among all tested
drugs in the BBB model. For valproic acid, which is also
transported by OATPs (Taogoshi et al., 2005), higher Papp
values were measured in the Caco-2 and lower in the MDCK
cell lines than in the EPA model. In the BBB model, baclofen
had significantly higher Papp compared to the two epithelial
cell lines. Similar results were obtained for baclofen on bovine
brain endothelial cells vs. epithelial culture models (Hakkarainen
et al., 2010). Among the LAT1 transported drugs, gabapentin,
which has a significant efflux transport by ABC transporters
(Nakanishi et al., 2013), had the lowest permeability on all
five models. The transfer of gabapentin across the VB-Caco-
2 cell line was below the detection limit, in accordance with
the strong efflux properties of this cell line (Hellinger et al.,
2012).
The gene expression of the tested two peptide transporters
was strikingly different among the models. A high level of
PEPT1 mRNA in the Caco-2 models and no expression in
EPA and MDCK models, in contrast a high transcript level
of PHT2 in the EPA model and no expression in Caco-2
models were measured, suggesting that peptide transport must
be very different on these models. PHT2 was identified
as a BBB-related SLC transporter in two independent
studies (Enerson and Drewes, 2005; Dahlin et al., 2009),
confirming our results. MFSD2A transports DHA in the form
of lysophosphatidylcholine in a sodium-dependent manner.
MFSD2A is selectively expressed in brain capillaries and mediate
the brain uptake of DHA. The brain endothelial expression of
MFSD2A is regulated by pericytes in vivo (Ben-Zvi et al., 2014).
This is the first study to compare the gene expression level of
this important BBB transporter in nine different models. The
MFSD2A gene was expressed in all models, except in GP8 and
RBE4 cell lines, and showed a higher mRNA expression in the
epithelial models and D3 cells than in the EPAmodel. All models
expressed high to moderate levels of mRNA for SLC transporters
of fatty acids, glycine, taurine, creatinine and vitamin C. There
was no significant difference in SLC transporter gene expression
between Caco-2 and VB-Caco-2 cells, except down-regulation
for MCT8. In the D3 cell line the highest expression among the
SLC transporters was for SAT2, followed by GLUT1, LAT1 and
MCT1 in our study, as well as in the literature (Carl et al., 2010;
Urich et al., 2012). Lithium treatment of D3 cells, which increase
BBB properties by the Wnt pathway (Weksler et al., 2013),
upregulated the expression level in half of the tested carrier and
transporter genes, such as GLUT3, -5, MCT8, SN1, SNAT5,
PEPT1, FATP1, ABCA2, GLYT1, TAUT, CRT, ASCT2.
Exogenous substrates of OATPs include antibiotics,
antidiabetic and anti-inflammatory drugs, antivirals,
antihistamines, antihypertensives, immunosuppressants,
and anticancer drugs, thus OATPs at the BBB are important
regulators of CNS drug disposition (Campos-Bedolla et al.,
2014). Statins were also identified as substrates of OATPs
(Kalliokoski and Niemi, 2009). There is an increasing interest
in statins to use them in neuronal diseases, such as stroke,
Parkinson’s disease, or Alzheimer’s disease (Malfitano et al.,
2014), but brain penetration is the key for their potential
therapeutic efficacy. In the present study, the permeability of
rosuvastatin, pravastatin and atorvastatin was compared on
five models. The higher penetration of the tested three statins
across the EPA model as compared to epithelial cells may be
explained by the higher expression of Oatp-1a2 and -1c1 influx
transporters in brain endothelial cells, and the stronger efflux
mechanisms, especially MRP2 in epithelial cells. In agreement
with our observation, very low apical to basal Papp values were
measured for rosuvastatin and atorvastatin in Caco-2 cells (Li
et al., 2011). In this article, the role of Pgp, BCRP, and MRP2 in
the efflux transport of these statin was also proven.
Tacrine and donepezil are two anticholinergic drugs
with good brain penetration, approved for the treatment of
Alzheimer’s disease. Using an immortalized brain endothelial
cell line, the organic cation transporter-2 (OCT2, SLC22A2),
the organic cation/carnitine transporter OCTN2 (SLC22A5),
and the choline transporter CHT1 (SLC5A7) were identified
as influx transporters of these drugs (Kang et al., 2005; Lee
et al., 2012). We also found a high permeability for both
drugs on the EPA BBB model. The endogenous cationic
metabolites choline and carnitine could significantly inhibit
the penetration of tacrine and donepezil, indicating that
the drugs and the endogenous ligands may share common
transporters. Lower permeability was measured for these
two drugs on VB-Caco-2 cells, and for donepezil the basal
to apical permeability was higher, in contrast to the EPA
model.
In conclusion, our study reveals major differences in the
gene expression patterns between the primary cell-based BBB
model and epithelial or brain endothelial cell lines for several
key BBB related genes. Epithelial cell line models showed
appropriate paracellular tightness, even if the pattern for TJ
protein genes were distinct between epithelial cell lines and the
BBB model. Disparity in the gene expression of transporters
between BBB and epithelial models were also reflected in the
permeability of selected drugs. These findings emphasize the
growing importance of SLC-mediated drug targeting to brain and
the use of appropriate culture models. Among the tested culture
models, the primary cell-based EPA model is suitable for the
functional analysis of the BBB.
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